Advocacy intelligence hub — real-time data for patient organizations
Xifaxan: FDA approved
Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Xifaxan
(rifaximin)Orphan drugSalix Pharmaceuticals, Inc.
Rifamycin Antibacterial [EPC]
12.1 Mechanism of Action Rifaximin is an antibacterial drug [see Clinical Pharmacology ( 12.4 )].